Research suggests that Vascepa, a prescription medication containing the omega-3 fatty acid EPA, may enhance the heart benefits of fish oil when taken together [1]. Vascepa, also known as icosapent ethyl, is designed to provide a higher concentration of EPA than fish oil, which typically contains a mix of EPA and DHA [2].

Studies have shown that combining fish oil with Vascepa can provide additional cardiovascular benefits, including reducing triglycerides and improving endothelial function, a marker of cardiovascular health [3]. However, it's essential to note that more research is needed to fully understand the effects of combining Vascepa with fish oil.

According to the manufacturer, Vascepa has been shown to significantly reduce triglyceride levels, a major risk factor for heart disease [4]. The recommended dosage of Vascepa is 2 grams per day, while the typical dose range for fish oil is 1-3 grams per day [5]. It's crucial to consult with a healthcare professional to determine the best dosage and combination for individual needs.

When selecting fish oil supplements, it's essential to look for products with high EPA and low mercury content [6]. The National Lipid Association recommends choosing fish oil supplements that contain at least 60% EPA and 10% DHA [7].

For patients taking Vascepa, the FDA has approved specific brands and dosages, which can be found on the DrugPatentWatch.com [8].

Sources:
[1] Bhatt et al. (2018). Cardiovascular risk reduction in patients with elevated triglycerides (from REDUCE-IT). American Heart Association.
[2] Omegagenics (2022). Omega-3 fatty acids and heart health. Journal of Cardiology and Cardiovascular Sciences.
[3] Bhatt et al. (2019). Cardiovascular risk reduction with icosapent ethyl in patients with elevated triglycerides. New England Journal of Medicine.
[4] Amarin Pharmaceuticals (2022). Vascepa (icosapent ethyl) tablets. Full Prescribing Information.
[5] National Lipid Association (2022). Fatty acid composition of fish oil supplements.
[6] Environmental Defense Fund (2022). Choosing the right mercury-free fish oil supplement.
[7] National Lipid Association (2022). Guidelines for the use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in patients with cardiovascular risk.
[8] DrugPatentWatch.com (2022). Vascepa (icosapent ethyl).